Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study

Por Kankesan, J., Shepherd, F.A., Peng, Y., Darling, G., Li, G., Kong, W., Mackillop, W.J., Booth, C.M.
Publicado em 2013

Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk

Por Liu, G, Gramling, S, Munoz, D, Cheng, D, Azad, AK, Mirshams, M, Chen, Z, Xu, W, Roberts, H, Shepherd, FA, Tsao, MS, Reisman, D
Publicado em 2011

Malignant mesothelioma: Canadian perspective and research directions

Por Lee, C.W., Martin, J., MacRae, R., Tsao, M.S., Nguyen, E., Johnston, M., Baas, P., Laurie, S., Feld, R., Murray, N., Shepherd, F.A.
Publicado em 2008

The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national conse...

Por Ellis, P.M., Morzycki, W., Melosky, B., Butts, C., Hirsh, V., Krasnoshtein, F., Murray, N., Shepherd, F.A., Soulieres, D., Tsao, M.S., Goss, G.
Publicado em 2009

A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC). A study of the PMH Phase II Consortium

Por Leighl, NB, Laurie, SA, Chen, XE, Ellis, P, Shepherd, FA, Knox, JJ, Goss, G, Burkes, RL, Pond, GR, Dick, C, Yen, Y, Zwiebel, JA, Moore, MJ
Publicado em 2009